Holistic Approaches to COVID-19: The Role of Zinc, Vitamin D, and Curcumin

Just a couple of years ago, the COVID-19 pandemic turned the world upside down. While vaccines and antiviral drugs grabbed the spotlight of politicians and the mainstream media, there’s a growing buzz around natural substances that could help us fight off the virus and boost the immune system. This article dives deep into studies, shedding light on both pharmaceutical and natural approaches to tackling COVID-19.

The Cautionary Tale of Paxlovid/Nirmatrelvir

In a study published in the Journal of Infectious Diseases, researchers examined nirmatrelvir and found that while it could reduce long-term COVID-19 symptoms, it came with potential side effects like nausea and diarrhea, which could be a dealbreaker for some people. The authors noted caution against its use due to possible side effects, including gastrointestinal issues and a need for more comprehensive research to validate these findings [1].

Another study, published in the Journal of the American Medical Association, presents a randomized controlled trial (RCT) on nirmatrelvir. Although it significantly reduced hospitalizations, the study also highlighted gastrointestinal issues, emphasizing the need for careful patient monitoring. The RCT involved a diverse cohort of participants, stratified by age, sex, and underlying health conditions, ensuring a comprehensive understanding of nirmatrelvir's effects across different populations. The authors underscored that despite its purported effectiveness, the drug’s side effects could outweigh its advantages in some patients, particularly those with pre-existing gastrointestinal conditions [2].

Nirmatrelvir, as an antiviral, inhibits the 3CL protease enzyme, crucial for the replication of SARS-CoV-2. This inhibition can also affect similar enzymes in the gastrointestinal tract, leading to disturbances like aforementioned nausea and diarrhea [1] [2].

A recent study titled "The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants" explored the phenomenon of viral and symptom rebound in patients treated with Paxlovid. The study found that viral rebound incidence was 14.2% in the Paxlovid group compared to 9.3% in the control group. Additionally, symptom rebound incidence was higher in the Paxlovid group (18.9%) compared to the control group (7.0%). These findings suggest that while Paxlovid may be effective in reducing initial viral load and symptoms, it is associated with a higher likelihood of rebound, which could complicate recovery and treatment strategies [3].

This rebound phenomenon can be attributed to its pharmacodynamics and interaction with the immune system. Paxlovid, a combination of nirmatrelvir and ritonavir, works by inhibiting the protease enzyme essential for the replication of SARS-CoV-2. While this mechanism is effective in reducing viral load and preventing severe disease progression, it can also interfere with the natural immune response. The suppression of viral replication can delay the immune system's full activation, leading to a scenario where, upon completion of the treatment, the virus can rebound as the immune system has not been fully primed to combat the infection. Additionally, ritonavir, a component of Paxlovid, is known to inhibit cytochrome P450 enzymes, leading to potential drug-drug interactions and liver enzyme abnormalities.

Further, a comprehensive review published in International Immunopharmacology explored the interplay between COVID-19 and liver disease severity. The study highlighted that individuals infected with COVID-19, particularly those with pre-existing liver conditions, often exhibit elevated liver enzymes. This elevation can be attributed to the direct hepatic effects of the virus, immune-mediated inflammatory responses, and drug-induced liver injury (DILI) from treatments like antivirals. The review discussed how medications, including those used to treat COVID-19, can exacerbate liver conditions by causing hepatocyte damage through various mechanisms such as oxidative stress and mitochondrial dysfunction. The inhibition of liver enzymes by ritonavir in Paxlovid can further stress the liver, leading to elevated liver enzyme levels and potential liver damage, especially in patients with pre-existing hepatic conditions [4].

Zinc: An Essential Mineral for Immune Function

A recent study titled "Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019" highlights the potential of zinc as a powerful ally in the fight against COVID-19. This randomized, double-blind, placebo-controlled trial involved 470 COVID-19 patients, who received either oral zinc supplements or a placebo for 15 days. The primary goal was to observe whether zinc could reduce the 30-day mortality rate and the need for ICU admission. Remarkably, the results showed a 30% reduction in ICU admissions among those taking zinc, along with shorter hospital stays and decreased duration of COVID-19 symptoms for outpatients. Importantly, no severe adverse effects were reported, underscoring zinc's safety profile. These findings support zinc as a valuable addition to COVID-19 treatment regimens, offering a natural and accessible option to enhance recovery [5].

A review published in the Mediterranean Journal of Nutrition and Metabolism further sheds light on zinc's crucial role in both the pathogenesis and treatment of COVID-19. The review highlights how low zinc levels can predispose individuals to severe COVID-19, making zinc supplementation a promising approach, especially for those who are deficient. Zinc supports cellular immunity, reduces inflammation, and has antiviral effects that inhibit the replication of viruses like SARS-CoV-2. Various studies show that zinc can enhance the effectiveness of antiviral drugs, reduce hospital stays, and potentially lower mortality rates [6].

Another review titled "Potential Role of Zinc, an Essential Trace Element with Antioxidant Properties in the Prevention and Management of COVID-19," published in the Journal of Biological Regulators & Homeostatic Agents, explores zinc's promising role in both preventing and managing COVID-19. Zinc can disrupt the SARS-CoV-2 virus's lifecycle by interfering with viral entry, replication, and assembly. It also enhances immune responses, reduces inflammation, and mitigates oxidative stress, all crucial in combating severe COVID-19 effects [7].

A review from the Cleveland Clinic Journal of Medicine examines the potential role of supplements like zinc, vitamin D, ascorbic acid (vitamin C), and N-acetylcysteine (NAC) in the prevention and treatment of COVID-19. These supplements are known for their immune-boosting and antioxidant properties. Zinc enhances antibody production and potentially inhibits viral replication. Thus, their biological plausibility and safety profile make them worthy candidates for further research [8].

A recent review titled "The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis," published in Frontiers in Immunology, highlights zinc's critical function in maintaining immune health and its potential as a cost-effective, globally available, and safe supplement to mitigate the impacts of the virus. Zinc plays a vital role in preserving the integrity of the respiratory epithelium, preventing viral entry, and reducing the risk of secondary bacterial infections. It also enhances ciliary clearance, essential for removing virus particles and reducing infection severity. The review discusses how zinc can inhibit viral replication by impairing viral polymerase function and protein synthesis. Moreover, zinc's anti-inflammatory and antioxidant properties help balance the immune response, potentially reducing the severity of COVID-19's hyper-inflammatory effects, such as the cytokine storm. Zinc deficiency, common in many COVID-19 risk groups, exacerbates infection risk and severity, emphasizing the need for zinc supplementation. With its ability to support antiviral immunity, reduce lung damage, and minimize secondary infections, zinc supplementation emerges as a crucial preventive and therapeutic strategy against COVID-19, particularly for those with suboptimal zinc levels [9].

A review titled "Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction," published in Reproductive Sciences, explores the multifaceted role of zinc in combating COVID-19 and its significant implications for reproductive health. Zinc deficiency is linked to worse outcomes in respiratory infections and mirrors many symptoms seen in COVID-19, such as multiorgan damage. The review delves into the detrimental impact of the cytokine storm and reactive oxygen species (ROS) overproduction during COVID-19, which can exacerbate zinc depletion and lead to severe oxidative stress and inflammation [10].

Importantly, zinc's role extends to reproductive health, where its deficiency can disrupt both male and female reproductive functions, affecting sperm quality, oocyte maturation, and embryo development. Zinc supplementation could protect reproductive health by improving oocyte and sperm quality, thereby potentially enhancing fertility outcomes during the pandemic [10].

A recent review published in Frontiers in Nutrition, titled "The Nutritional Roles of Zinc for Immune System and COVID-19 Patients," explores the essential role zinc plays in immune health and its potential benefits in managing COVID-19. The review emphasizes that zinc is a vital micronutrient crucial for immune system function, cellular activities, and the treatment of infectious diseases. Zinc deficiency can lead to significant immune system imbalances, making individuals more susceptible to viral infections, including COVID-19 [11].

The review details how zinc supports immune cell function, regulates cytokine production, and suppresses inflammation, thus reducing oxidative stress and enhancing the body's ability to fight infections. Zinc's antiviral properties are particularly notable in its ability to inhibit virus replication and improve outcomes in viral infections. Additionally, the review highlights the importance of maintaining adequate zinc levels through diet or supplementation, especially given the overlap between symptoms of zinc deficiency and those of COVID-19 [11].

A review published in Medical Hypotheses titled "Potential Role of Zinc Supplementation in Prophylaxis and Treatment of COVID-19," explores the multifaceted benefits of zinc in combating COVID-19. Zinc, known for its direct and indirect antiviral properties, plays a crucial role in enhancing both innate and humoral immunity. The review highlights how zinc supplementation can boost antiviral immunity, improve immune cell function, and potentially work synergistically with standard antiviral therapies [12].

Zinc's antiviral effects are realized through mechanisms such as virus attachment inhibition, membrane stabilization, and interference with viral replication processes. The authors discuss zinc's role in inhibiting viral protease and RNA-dependent RNA polymerase activities, which are crucial for viral replication. Given zinc's effectiveness against various viruses, including those similar to SARS-CoV-2, the review suggests that zinc supplementation could be beneficial for both the prevention and treatment of COVID-19. With the ongoing search for effective COVID-19 therapies, zinc presents a promising, accessible, and safe option to enhance immune defense and mitigate the virus's impact [12].

Vitamin D3: The Sun’s Immune Booster

A recent umbrella review titled "Vitamin D3 and COVID-19 Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses," published in Antioxidants, examines the relationship between vitamin D3 levels, supplementation, and COVID-19 outcomes. This comprehensive review consolidates findings from various systematic reviews and meta-analyses to provide a thorough evaluation of vitamin D3's impact on COVID-19 [13].

The review highlights that vitamin D3, known for modulating immune responses and inflammatory pathways, has a significant association with COVID-19 outcomes. The findings suggest that low levels of vitamin D3 are linked to increased severity and mortality of COVID-19. Specifically, the review found that insufficient vitamin D3 levels nearly doubled the risk of severe infection and increased the mortality risk by 83% [13].

Additionally, vitamin D3 supplementation was associated with reduced severity and mortality in COVID-19 patients, demonstrating highly suggestive evidence of benefit. Overall, this umbrella review underscores the potential of vitamin D3 supplementation as a preventive and therapeutic measure in managing COVID-19, especially for those with deficiencies [13].

A recent study published in Scientific Reports titled "Association between Vitamin D Supplementation and COVID-19 Infection and Mortality," investigates the potential benefits of vitamin D supplementation in reducing COVID-19 infection rates and related mortality. This extensive research focuses on a large cohort of U.S. veterans, analyzing the impact of vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol) supplements. The study found that vitamin D supplementation was associated with significant reductions in COVID-19 infection rates, with vitamin D3 showing a 20% reduction and vitamin D2 showing a 28% reduction compared to those who did not take supplements [14].

Furthermore, vitamin D3 supplementation was linked to a 33% reduction in mortality within 30 days of a COVID-19 infection, while vitamin D2 showed a 25% reduction, though the latter was not statistically significant. Subgroup analyses revealed that Black veterans experienced a greater reduction in infection rates with vitamin D supplementation than their White counterparts. Additionally, those with lower baseline vitamin D levels benefited more from supplementation, particularly when higher dosages were administered. For instance, patients with initial vitamin D levels between 0-19 ng/mL who received high dosages of vitamin D3 experienced the most significant reductions in infection rates [14].

A systematic review and meta-analysis titled "The Role of Vitamin D in the Age of COVID-19," published in the International Journal of Clinical Practice again explores the potential benefits of vitamin D in the prevention and treatment of COVID-19. This comprehensive analysis includes 23 studies with a total of 11,901 participants, examining the relationship between vitamin D status and COVID-19 outcomes. The review reveals that 41% of COVID-19 patients suffer from vitamin D deficiency, while 42% have insufficient levels of vitamin D. The average serum 25-hydroxyvitamin D concentration among COVID-19 patients was found to be 20.3 ng/mL [15]

Individuals with vitamin D deficiency were 3.3 times more likely to contract COVID-19 and 5.1 times more likely to develop severe disease compared to those with adequate vitamin D levels. However, there was no significant association between vitamin D deficiency and increased mortality rates. The authors emphasize the importance of maintaining adequate vitamin D levels to potentially reduce the risk of infection and severity of COVID-19 [15].

Curcumin: The Healing Power of Turmeric

A recent study titled "Antiviral, Anti-Inflammatory, and Antioxidant Effects of Curcumin and Curcuminoids in SH-SY5Y Cells Infected by SARS-CoV-2," published in Scientific Reports, explores the potential therapeutic effects of curcumin and its derivatives against COVID-19, particularly within neuronal cells. The research focuses on curcuminoids Me08 and Me23, as well as curcumin (CUR) and Curcuma longa extract (EXT), investigating their impact on human neuroblastoma SH-SY5Y cells infected with SARS-CoV-2 [14].

The study found that the curcuminoid Me23 significantly decreased the expression of key proteases involved in viral entry, such as TMPRSS2 and TMPRSS11D, thereby reducing the elevated levels of reactive oxygen species (ROS) induced by the virus. Me23 also demonstrated strong antioxidative properties by enhancing NRF2 gene expression and restoring NQO1 activity post-infection. Both Me08 and Me23 effectively inhibited SARS-CoV-2 replication in SH-SY5Y cells overexpressing ACE2 receptors. Additionally, all tested compounds (CUR, EXT, Me08, and Me23) were shown to lower levels of pro-inflammatory cytokines like IL-6, TNF-α, and IL-17, with Me08 specifically reducing INF-γ levels. These findings suggest that curcumin and its derivatives, particularly Me23, hold significant promise as therapeutic agents for mitigating the impact of COVID-19 on the central nervous system by leveraging their antiviral, antioxidant, and anti-inflammatory properties. This study underscores the potential of natural compounds in the ongoing search for effective COVID-19 treatments, highlighting the importance of further research into curcumin's mechanisms of action and clinical efficacy [16].

An additional systematic review of clinical trials highlighted curcumin's efficacy in reducing the severity and duration of COVID-19 symptoms, hospitalization time, and mortality rates in patients with mild to severe cases. The review encompassed six studies, all of which reported significant improvements in common COVID-19 symptoms such as cough, chills, myalgia, and taste and smell disturbances. Additionally, curcumin supplementation was linked to the reduction of the dreaded cytokine storm by modulating pro-inflammatory and anti-inflammatory cytokines, thus restoring immune balance. Notably, curcumin treatments led to increased levels of anti-inflammatory markers like IL-10, IL-35, and TGF-β, while reducing pro-inflammatory cytokines such as IL-1β and IL-6 [17].

Curcumin, the vibrant yellow compound found in turmeric, has shown promising results in combating COVID-19 symptoms. A systematic review of clinical trials highlighted its efficacy in reducing the severity and duration of COVID-19 symptoms, hospitalization time, and mortality rates in patients with mild to severe cases. The review encompassed six studies, all of which reported significant improvements in common COVID-19 symptoms such as cough, chills, myalgia, and taste and smell disturbances. Additionally, curcumin supplementation was linked to the reduction of the dreaded cytokine storm by modulating pro-inflammatory and anti-inflammatory cytokines, thus restoring immune balance. Notably, curcumin treatments led to increased levels of anti-inflammatory markers like IL-10, IL-35, and TGF-β, while reducing pro-inflammatory cytokines such as IL-1β and IL-6 [17].

Curcumin's benefits extend beyond symptomatic relief. Studies indicate its potential in decreasing the frequency of thromboembolic episodes post-COVID-19 recovery, further enhancing its therapeutic profile. Despite its poor bioavailability in native form, advanced formulations like nanoparticles and adjuvants have improved its absorption and efficacy. With no reported side effects in the reviewed trials, curcumin presents a safe adjunct therapy. Future research with larger, standardized clinical trials is essential to solidify curcumin's role in COVID-19 management [17].

A review titled "Curcumin as a Potential Treatment for COVID-19," published in Frontiers in Pharmacology, examines the multifaceted benefits of curcumin in combating COVID-19. Curcumin, a natural polyphenol derived from turmeric, has demonstrated significant antiviral, anti-inflammatory, and antioxidant properties, making it a promising candidate for COVID-19 therapy [18].

The review details curcumin's mechanisms of action, including its ability to inhibit viral replication, modulate immune responses, and reduce inflammation. In silico studies suggest that curcumin can bind to the spike protein and ACE2 receptor of SARS-CoV-2, potentially preventing the virus from entering host cells [18].

Additionally, curcumin inhibits key proteases like TMPRSS2 and the main protease (Mpro) involved in viral replication. Curcumin's anti-inflammatory effects are particularly relevant for COVID-19, as it can modulate the nuclear factor-kappa B (NF-κB) pathway, reducing the production of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, and IL-18. This modulation helps prevent the cytokine storm often seen in severe COVID-19 cases [18].

Moreover, curcumin has shown efficacy in reducing thromboembolic events and platelet aggregation, addressing another critical aspect of COVID-19 pathology. Clinical studies reviewed indicate that curcumin supplementation, especially in nanoencapsulated forms, significantly improves clinical outcomes in COVID-19 patients, reducing symptoms like fever, cough, and dyspnea, and lowering mortality rates. Its safety profile further supports its use as an adjunct therapy in managing COVID-19. In conclusion, the review highlights curcumin's potential as a versatile and effective therapeutic agent against COVID-19, emphasizing the need for further clinical trials to confirm these findings and explore its full potential in treating the disease [18].

Finally, a recent study published in Trials evaluated the efficacy of curcumin-piperine supplementation on the clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients. This randomized double-blind, placebo-controlled trial included 46 participants who received either curcumin-piperine capsules or a placebo for 14 days. Each capsule contained 500 mg of curcumin and 5 mg of piperine. The results showed a significant improvement in various health symptoms, such as dry cough, sputum cough, ague, sore throat, weakness, muscular pain, headache, and dyspnea in both groups by the end of the study.

Further, the curcumin-piperine group experienced a more pronounced reduction in weakness compared to the placebo group. However, despite these improvements, there were no significant changes in complete blood count, liver enzymes, blood glucose levels, lipid parameters, kidney function, or c-reactive protein levels between the two groups. This suggests that while curcumin-piperine supplementation can alleviate some COVID-19 symptoms, it does not significantly affect other clinical or biochemical indices [19].

Conclusion

The exploration of natural solutions for COVID-19 treatments highlights promising avenues that complement conventional pharmaceutical approaches. Given the side effects of drugs like Paxlovid, zinc, vitamin D, and curcumin present compelling evidence for their antiviral, anti-inflammatory, and immune-boosting properties.

Zinc and vitamin D, in particular, have shown significant potential in reducing severity and improving recovery in COVID-19 patients. Curcumin, with its multifaceted benefits, stands out as a powerful adjunct therapy, capable of mitigating symptoms and enhancing immune response without major side effects. These findings underscore the importance of integrating natural compounds into COVID-19 treatment regimens, offering a holistic approach to combating the virus and enhancing patient outcomes.

 

References

[1] Xie, Y., Bowe, B., & Al-Aly, Z. (2022). Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19. Journal of Infectious Diseases. doi.org/10.1001/jamainternmed.2023.0743

[2] Hammond, J., Leister-Tebbe, H., Gardner, A., et al. (2022). Association of Nirmatrelvir for Acute SARS-CoV-2 Infection With Reduced Hospitalization and Death in the First 30 Days. Journal of the American Medical Association. doi.org/10.1002/jmv.29333

[3] Pandit, J. A., Radin, J. M., Chiang, D., Spencer, E., Pawelek, J., Diwan, M., ... & Mina, M. (2022). The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants. medRxiv. doi.org/10.1101/2022.11.14.22282195

[4] Imam, M. T., Almalki, Z. S., Alzahrani, A. R., Al-Ghamdi, S. S., Falemban, A. H., Alanazi, I. M., Shahzad, N., Alrooqi, M. M., Jabeen, Q., & Shahid, I. (2023). COVID-19 and severity of liver diseases: Possible crosstalk and clinical implications. International Immunopharmacology, 121, 110439. doi.org/10.1016/j.intimp.2023.110439

[5] Ben Abdallah, S., Mhalla, Y., Trabelsi, I., Sekma, A., Youssef, R., Bel Haj Ali, K., Ben Soltane, H., Yacoubi, H., Msolli, M. A., Stambouli, N., Beltaief, K., Grissa, M. H., Khrouf, M., Mezgar, Z., Loussaief, C., Bouida, W., Razgallah, R., Hezbri, K., Belguith, A., Belkacem, N., … Nouira, S. (2023). Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(2), 185–191. doi.org/10.1093/cid/ciac807

[6] Rezazadeh, A., Sadeghzadeh, S., Namakin, K., Tamimi, A., & Khanjani, Z. (2022). The role of zinc in the pathogenesis and treatment of COVID-19: A review. Mediterranean Journal of Nutrition and Metabolism, 15(2), 143–159. doi.org/10.3233/mnm-211524

[7] Bhagyalakshmi Nair, Aparna Ashokan, Veena Gopalakrishnan Prema, Girish Banavara Narasimhamurthy, Rajesh Gopalakrishna, Devika Vadhyaruparambil Padamakumar, Lekshmi R. Nath, Anca Oana Docea, Javad Sharifi-Rad, Daniela Calina. Potential Role of Zinc, an Essential Trace Element with Antioxidant Properties in the Prevention and Management of COVID-19. Journal of Biological Regulators and Homeostatic Agents. 2023, 37(11): 5757-5768 doi.org/10.23812/j.biol.regul.homeost.agents.20233711.552

[8] Bauer, S. R., Kapoor, A., Rath, M., & Thomas, S. A. (2020). What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19?. Cleveland Clinic journal of medicine. Advance online publication. doi.org/10.3949/ccjm.87a.ccc046

[9] Wessels, I., Rolles, B., & Rink, L. (2020b). The potential impact of zinc supplementation on COVID-19 pathogenesis. Frontiers in Immunology, 11. doi.org/10.3389/fimmu.2020.01712

[10] Sethuram, R., Bai, D., & Abu-Soud, H. M. (2022). Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction. Reproductive sciences (Thousand Oaks, Calif.), 29(1), 1–6. doi.org/10.1007/s43032-020-00400-6

[11] Jin, D., Wei, X., He, Y., Zhong, L., Lu, H., Lan, J., Wei, Y., Liu, Z., & Liu, H. (2024). The nutritional roles of zinc for immune system and COVID-19 patients. Frontiers in nutrition, 11, 1385591. https://doi.org/10.3389/fnut.2024.1385591

[12] Kumar, A., Kubota, Y., Chernov, M., & Kasuya, H. (2020). Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. Medical hypotheses, 144, 109848. doi.org/10.1016/j.mehy.2020.109848

[13] Petrelli, F., Oldani, S., Borgonovo, K., Cabiddu, M., Dognini, G., Ghilardi, M., Parati, M. C., Petro', D., Dottorini, L., Rea, C., Lonati, V., Luciani, A., & Ghidini, A. (2023). Vitamin D3 and COVID-19 Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. Antioxidants (Basel, Switzerland), 12(2), 247. doi.org/10.3390/antiox12020247

[14] Gibbons, J. B., Norton, E. C., McCullough, J. S., Meltzer, D. O., Lavigne, J., Fiedler, V. C., & Gibbons, R. D. (2022). Association between vitamin D supplementation and COVID-19 infection and mortality. Scientific Reports, 12(1). doi.org/10.1038/s41598-022-24053-4

[15] Ghasemian, R., Shamshirian, A., Heydari, K., Malekan, M., Alizadeh-Navaei, R., Ebrahimzadeh, M. A., Ebrahimi Warkiani, M., Jafarpour, H., Razavi Bazaz, S., Rezaei Shahmirzadi, A., Khodabandeh, M., Seyfari, B., Motamedzadeh, A., Dadgostar, E., Aalinezhad, M., Sedaghat, M., Razzaghi, N., Zarandi, B., Asadi, A., Yaghoubi Naei, V., … Shamshirian, D. (2021). The role of vitamin D in the age of COVID-19: A systematic review and meta-analysis. International journal of clinical practice, 75(11), e14675. doi.org/10.1111/ijcp.14675

[16] Nicoliche, T., Bartolomeo, C. S., Lemes, R. M. R., Pereira, G. C., Nunes, T. A., Oliveira, R. B., Nicastro, A. L. M., Soares, É. N., Da Cunha Lima, B. F., Rodrigues, B. M., Maricato, J. T., Okuda, L. H., De Sairre, M. I., Prado, C. M., Ureshino, R. P., & Stilhano, R. S. (2024). Antiviral, anti-inflammatory and antioxidant effects of curcumin and curcuminoids in SH-SY5Y cells infected by SARS-CoV-2. Scientific Reports, 14(1). doi.org/10.1038/s41598-024-61662-7

[17] Vahedian-Azimi, A., Abbasifard, M., Rahimi-Bashar, F., Guest, P. C., Majeed, M., Mohammadi, A., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2022). Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: a systematic review of clinical trials. Nutrients, 14(2), 256. doi.org/10.3390/nu14020256

[18] Rattis, B. a. C., Ramos, S. G., & Celes, M. R. N. (2021). Curcumin as a potential treatment for COVID-19. Frontiers in Pharmacology, 12. doi.org/10.3389/fphar.2021.675287

[19] Askari, G., Sahebkar, A., Soleimani, D., Mahdavi, A., Rafiee, S., Majeed, M., Khorvash, F., Iraj, B., Elyasi, M., Rouhani, M. H., & Bagherniya, M. (2022). The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial. Trials, 23(1). doi.org/10.1186/s13063-022-06375-w